Ozempic Alternative Ditches The Needle And One Major Side Effect
https://www.sciencealert.com/ozempic-alternative-ditches-the-needle-and-one-major-side-effect
Excerpt:
A drug that can be taken orally could soon rival the likes of Ozempic for treating type 2 diabetes and obesity, according to a new study. Although its efficacy hasn’t yet been tested in humans, the compound could bypass some of the harmful side-effects associated with similar drugs.
Unlike the famous family of GLP-1 receptor agonist drugs, this new candidate targets the β2-adrenergic receptor (β2AR). Drugs that do this aren’t new: salbutamol (sold as Ventolin among other brand names) is widely prescribed for use in short stints to treat asthma and chronic obstructive pulmonary disease.
Clenbuterol is also prescribed for asthma in some countries, though it’s better known as a performance-enhancing drug, banned by the World Anti-Doping Agency for its anabolic effects.
For more than a decade, scientists have been trying to find a way to harness the benefits of β2AR agonists, without setting off their harmful effects. They can stimulate skeletal muscle glucose uptake and burn fat, mimicking the effects of exercise – but they have been considered too risky for treating diabetes or obesity, because of their tendency to wreak havoc on the heart.
The body’s β2-adrenergic receptors are coupled with G proteins, and when activated for long periods (by β2AR drugs, for instance), the G proteins set off a chain reaction which leads to cardiovascular problems.
“That would lead to heart rate increases, systolic blood pressure increases, and, eventually, that over-sustained exposure would lead to increases in heart weight and cardiac hypertrophy,” molecular biologist Shane Wright, from Karolinska Institute in Sweden, told Mar de Miguel of Bioworld.
But a campaign led by scientists from the Karolinska Institute, Stockholm University, and the biotech company Atrogi AB has revealed a series of β2AR agonist molecules that can side-step the slippery slope triggered by the G proteins.
By activating only specific pathways, one of these – dubbed ‘compound 15’ – seems less likely to cause those concerning side effects, though we won’t know for sure until further clinical trials are carried out.
Unlike GLP-1 receptor agonists like Ozempic, compound 15 doesn’t suppress appetite or lead to muscle loss, which means it may be safer in that regard too. It’s also much more user-friendly, as a drug that can be swallowed rather than injected.
*************
More hype about a drug to potentially challenge Ozempic, Wegovy and the like before they even have clinical trials. Big pharma salivating about drug solutions, instead of lifestyle changes, to obesity and Type 2 diabetes epidemic.
Miami Vice meets Looney Tunes:
Florida beachgoer finds nearly half a million dollars of cocaine wrapped in “Yosemite Sam” packaging
https://x.com/WCSOFL/status/1939401990599061696
Excerpt:
This morning, a beachgoer discovered nearly a half a million dollars of cocaine washed up on a Walton County Beach.
The 25 kilos marked with Yosemite Sam were confiscated and logged into evidence.
While enjoying our beautiful beaches, if you come across any square groupers, PLEASE call
@WCSOFL
immediately and DO NOT touch suspicious packages. The contents could be extremely harmful.
We’re here if you need us.